Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

orward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2013201220132012REVENUES:

$
-$
23,996$
,361$
2,705OPERATING EXPENSES:Research and development

2,944,5874,705,6627,733,6709,683,112General and administrative

1,079,1971,344,8613,141,7513,473,990Total operating expenses

4,023,7846,050,52310,875,42113,157,102Loss from operations

(4,023,784)(6,026,527)(10,865,060)(13,094,397)OTHER INCOME (EXPENSE):Investment income


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/24/2014)... 24, 2014 As part of the ... in the MENA region during 2014 with potential global ... provider agreement with DZS to manage our clinical trials ... Global VP of R&D and President of SBI pharmaceuticals ... operational practices with a focus on utilizing eClinical software ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") ... in a Phase 1b clinical trial of PX-12 ... proprietary small molecule,inhibitor of thioredoxin, a protein that ... survival and drug resistance of,many cancers., The ...
... and present a poster on proprietary siRNA ... targeting and ... Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing novel,RNA ... Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on June ...
... Calif., June 10 DURECT Corporation,(Nasdaq: DRRX ... (NDA) for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to ... investigational drug, is a long,acting oral formulation of ... on DURECT,s ORADUR technology, Remoxy is designed to ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5
(Date:7/24/2014)... This news release is available in German . ... that there are 300 million asthma sufferers worldwide, a ... up to 30% of the global population contending with ... inflammatory diseases can also affect other organs and parts ... occur in the intestine (in the form of inflammatory ...
(Date:7/24/2014)... news release is available in German . ... welcomed in Norway and they are a common sight on ... that electric cars topped the list of new vehicle registrations ... the situation in Germany, where electric vehicles claim only a ... on the roads in Germany, only a mere 8000 are ...
(Date:7/24/2014)... in German . ... respond to threats to health, and to provide life-long ... the mechanism underlying immunologic memory, however, has remained elusive. ... support the hypothesis that the persistence of immune memory ... potential. Until now, there was no conclusive evidence, largely ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... 2011 With millions of people warding off winter,s ... raising red flags about the potential health effects of ... in the American Chemical Society,s (ACS,) journal, Chemical ... inhaled into the lungs from wood smoke may have ...
... Darwin, the "tree of life" has been the preeminent metaphor ... changing of individual species. The discovery that a large ... species of fungus to another, however, significantly strengthens the argument ... more appropriate. "The fungi are telling us something important ...
... reports that family mealtimes that contain three ingredients in the ... who have chronic asthma. "Family mealtimes, when they,re done ... reduced risk of substance abuse, eating disorders, and obesity. In ... we can see minute by minute which factors deliver these ...
Cached Biology News:Discovery of jumping gene cluster tangles tree of life 2Discovery of jumping gene cluster tangles tree of life 3Recipe for family mealtimes calls for 3 ingredients in the right amounts 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: